Regarding information being kept from investors. I suggest, a simple read, on the investor web site.
recently updated for Sept.
Give it a read:
quick recap
They prejected an estimated $2.5 billion in annual sales. That being for the MBc alone.
additionally the projected pancreatic sales.
I know a hard concept, but a company's day- day share price, has zero implications with the ability of a drug approval.
oncolytics biotech can only reach its full potential if when Pelareorep gets approved.
prior to that, they must get a business partener , or complete buyout.
So , if you belive the science is correct & they can get approval, wait it out.
Alternatively, if you do not think the science is wrong.
then sell & move on.
myself?
They have sucsess in 4/5 G.I. Trials with Roche.
To the point that all met entry criteria & are moving forward.
To the point that from a $5million grant they are adding an additional arm.
FDA fast track designation of both the pancreatic cancer cotherapy & the MBc. Cotherapy.
Please don't take my word.
Go to the Onc site, take a read. Substantial details.
Then decide. Can Pelareorep be of help as a cotherapy for cancer.
That decision is based on interpretation of the science, not the shareprice.
In 1999 I could have bought Apple shares for just under $1. I did not afteall, must be doomed!
One of the worst investment decisions I ever made. I looked @ the SP and did not understand the technology.
Im not comparing Onc to apple, so save any silly rhetoric. I am comparing my understanding of the " company " vs " the stock price"
Absolutely, 100% we buy the shares to some day sell for a profit.
The easiest way to realize that is a corporate buyout.
The MBc data is barely a few months announced.
There is now full details available for a larger pharma to step in.
Time line? A lot qicker than many think.
notice not a peep on the web site on partnering.
Has been very quiet. Call it calm before the storm. Hopefully a good news storm.
Again, I see a buyout. More than $1billion, less than $3 billion.
The $2.5 billion in sales projected has great future value. They do have to pay for the company, the trial & the marketing.
Additionally, should they find a way to wait it out. Then the price goes up, if/ when Pela is approved for pancreatic cancer.
For those who have not, please go to investopedia & read up on startup biotech evaluations.
That being " what are they worth".
in all cases it has To do with present value of future income....absolutely zero to do with trading price at anytime.
Perhaps a bit much for some.
start with the company presentation.to understand the technology
thenl
read up on biotech evaluations, to understand what Onc could be worth.
Night all